A Phase 2 interventional study of Sedation with sevoflurane during 48-hr in ICU in Obesity, sponsored by University Hospital, Clermont-Ferrand. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-06-27.
Sponsored by University Hospital, Clermont-Ferrand · Phase 2, Interventional, and Treatment
Describing a pharmacokinetic model of 48-h sevoflurane sedation in obese ICU patients
Prospective clinical monocentric study in ICU with sedated ventilated obese patients with sevoflurane during 48 h with the AnaConda® system, establishing pharmacokinetic model of sévoflurane and its metabolites (hydroxyfluroisopropanol, fluoride)
6,296 studies on the registry are indexed under Obesity; 1,692 are open to participants now.
This study's enrollment of 8 is below the median of 78 across 4,878 interventional studies indexed under Obesity.
Browse Obesity studies →University Hospital, Clermont-Ferrand is the lead sponsor of 841 studies on the registry; 178 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Determination of plasmatic concentrations of sevoflurane at different times of a 48h sedation of sevoflurane in obese ICU patients
Drug: Sedation with sevoflurane during 48-hr in ICU
Also known as: Determination of plasmatic concentrations of sevoflurane at different times of a 48h sedation of sevoflurane in obese ICU patients
Determination of plasmatic concentrations of sevoflurane before using AnaConda® system
Time frame: at 5min, 60 min, 24 hrs and just before the end of sedation.
Determination of plasmatic concentrations of HFIP and fluoride before using AnaConda® system
Time frame: at 5min, 60 min, 24 hrs and just before the end of sedation.
This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Clermont-Ferrand